
CORD-19:3c1f47a07aaf0e393dee9fbd08596a4b9f4f0a03 / 334097-334414
Annnotations
CORD-19-Sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T2556 | 0-317 | Sentence | denotes | While in vitro triazole (particularly fluconazole) susceptibility results for Candida appear to be optimally correlated with clinical outcome, data are either limited and investigational or fail to demonstrate any significant in vitro-in vivo correlation for most of the remaining fungus-antifungal drug combinations. |
T54400 | 0-317 | Sentence | denotes | While in vitro triazole (particularly fluconazole) susceptibility results for Candida appear to be optimally correlated with clinical outcome, data are either limited and investigational or fail to demonstrate any significant in vitro-in vivo correlation for most of the remaining fungus-antifungal drug combinations. |
CORD-19_Custom_license_subset
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T292 | 0-317 | Sentence | denotes | While in vitro triazole (particularly fluconazole) susceptibility results for Candida appear to be optimally correlated with clinical outcome, data are either limited and investigational or fail to demonstrate any significant in vitro-in vivo correlation for most of the remaining fungus-antifungal drug combinations. |
Epistemic_Statements
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T718 | 0-317 | Epistemic_statement | denotes | While in vitro triazole (particularly fluconazole) susceptibility results for Candida appear to be optimally correlated with clinical outcome, data are either limited and investigational or fail to demonstrate any significant in vitro-in vivo correlation for most of the remaining fungus-antifungal drug combinations. |